It has the advantage of inducing cell death in a highly selective manner, allowing it to target cancer cells while sparing normal cells.1,2 This selectivity reduces the adverse reactions that are frequently associated with standard cancer treatments.1 The TRAIL has also shown promise in overcoming resistance to chemotherapy and radiation therapy. Here, TNFSF10 is linked to cancer.